C4X Discovery Holdings
plc
("C4XD", "C4X
Discovery" or the "Company")
Result of General
Meeting
15 April
2024 - C4X Discovery Holdings plc
(AIM: C4XD), a pioneering Drug Discovery company, announces that at
the Company's General Meeting held earlier today all resolutions
were duly passed.
Accordingly, pursuant to the passing of
Resolution 1, cancellation of admission of the Company's ordinary
shares to trading on AIM will become effective at 7.00 a.m. on 26
April 2024.
In accordance with the passing of Resolution 2,
the Company will re-register as a private limited company with the
name C4X Discovery Holdings Limited and adopt new articles of
association, which is expected to take place in the week commencing
29 April 2024.
The results of
the proxy votes received ahead of the meeting are outlined in the
table below:
Resolution
|
Votes For
|
Votes
Against
|
Vote
Withheld
|
Total Votes Cast (excluding
Withheld)
|
No.
of shares
|
% of
shares voted
|
No.
of shares
|
% of
shares voted
|
No.
of shares
|
|
1
|
171,600,106
|
93.07%
|
12,787,116
|
6.93%
|
10,967,843
|
184,387,222
|
2
|
171,694,784
|
93.12%
|
12,689,256
|
6.88%
|
10,971,025
|
184,384,040
|
Shareholders
are reminded that the last day of dealings in C4X Discovery's
ordinary shares on AIM will be 25 April 2024.
With effect from the cancellation of admission
of the Company's ordinary shares to trading on AIM, the Company
intends to implement a matched bargain facility and has appointed
Asset Match (www.assetmatch.com) to facilitate trading in the
Ordinary Shares. This facility will allow Shareholders and new
investors to trade Ordinary Shares by matching buyers and sellers
through periodic auctions. Full details will be made available to
shareholders on the Company's website at www.c4xdiscovery.com and
directly by letter or e-mail (where appropriate).
From the date of cancellation, shareholder will
be able to request Company news alerts via email on the C4XD
website.
Further details regarding the cancellation and
re-registration are set out in the circular sent to shareholders
dated 27 March 2024. A copy of the circular is available on the
Company's website www.c4xdiscovery.com.
- Ends -
Contacts
C4X Discovery
Holdings
|
|
Mo Noonan, Communications
|
+44 (0)787 6444977
|
|
|
Panmure Gordon
(UK) Limited (NOMAD and Broker)
|
|
Freddy Crossley, Emma Earl (Corporate
Finance)
|
+44 (0)20 7886 2500
|
Rupert Dearden (Corporate Broking)
|
|
|
|
C4X Discovery
Media - Consilium Strategic Communications
|
|
Mary-Jane Elliott, Chris Gardner
|
+44 (0)203 709 5700
|
Notes to
Editors:
About C4X
Discovery
C4X Discovery (C4XD) is a pioneering Drug Discovery
company, combining scientific expertise with cutting-edge
technologies to efficiently deliver world‑leading medicines. We
have a highly valuable and differentiated approach to Drug
Discovery through our enhanced molecular design and patient
stratification capabilities, generating small molecule drug
candidates across multiple disease indications focused on
immuno-inflammation. We are advancing our internal portfolio which
ranges from early-stage target opportunities to late-stage Drug
Discovery programmes and we have two commercially partnered
programmes with Sanofi and AstraZeneca, and one clinical stage
candidate which has been acquired by Indivior.
For more information visit us at www.c4xdiscovery.com or follow us
on twitter @C4XDiscovery.
EXPECTED TIMETABLE OF PRINCIPAL
EVENTS
Event
|
Time and/or
date(1)(2)
|
Announcement of proposed Cancellation,
Re-registration and adoption of New Articles
|
27 March
2024
|
Publication and posting of the Circular and the
Form of Proxy
|
27 March
2024
|
Latest time for receipt of proxy appointments
in respect of the General Meeting
|
11.00 a.m. on 11
April 2024
|
General Meeting
|
11.00 a.m. on 15
April 2024
|
Announcement of result of General
Meeting
|
15 April
2024
|
Last day of dealings in Ordinary Shares on
AIM
|
25 April
2024
|
Cancellation
|
7.00 a.m. on 26 April
2024
|
Commencement of Matched Bargain
Facility
|
26 April
2024
|
Expected re-registration as a private
company
|
week commencing 29
April 2024
|
Notes:
(1)
All of the times referred to in this announcement refer to London
time, unless otherwise stated.
(2)
The timetable above assumes that the Resolutions set out in the
Notice of General Meeting are passed. Events listed in the above
timetable following the General Meeting are conditional on the
Resolutions being passed at the General Meeting without
amendment.
(3)
Each of the times and dates in the above timetable is subject to
change. If any of the above times and/or dates change, the revised
times and dates will be notified to Shareholders by an announcement
through a Regulatory Information Service.